Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417437 | 0.87 | MEN1 (0.41) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5378069 | 0.87 | CYP1A2 (0.47) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5378052 | 0.85 | MEN1 (0.41) | APPMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5378771 | 0.85 | TDP1 (0.56) | APPMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5381872 | 0.85 | L3MBTL1 (0.56) | APPMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5377736 | 0.85 | LMNA (0.47) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5375690 | 0.84 | RAB9A (0.45) | APPMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5398160 | 0.84 | MEN1 (0.39) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5387366 | 0.83 | APP (0.42) | APPMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5373469 | 0.82 | MAOB (0.41) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | APP 3076/4885MEN1 2386/4885KMT2A 2219/4885 |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | APP 3108/4885MEN1 2301/4885KMT2A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.